Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07418229 | Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine | PHASE1 | NOT YET_RECRUITING | 60 | — | — | Mar 9, 2026 | May 30, 2027 | Feb 18, 2026 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| Sinovac RSV mRNA vaccine low-dose group | EXPERIMENTAL | Participants will receive one dose of low-dose lyophilized RSV mRNA vaccine. |
| Sinovac RSV mRNA vaccine high-dose group | EXPERIMENTAL | Participants will receive one dose of high-dose lyophilized RSV mRNA vaccine. |
| Placebo control group | PLACEBO_COMPARATOR | Participants will receive one dose of normal saline. |
| Name | Type | Description |
|---|---|---|
| Low-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in low dosage |
| High-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in high dosage |
| Placebo | OTHER | Participants will receive one dose of normal saline. |
Inclusion Criteria: 1. Participants can understand and voluntarily sign the informed consent form; 2. Able to provide legal identity documents; 3. Healthy individuals aged 18 years and above; 4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contracepti...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Moderna, Inc. | MRNA | 3 | PHASE3 | mRNA-1345, mRNA-1365, Nimenrix |
| Pfizer Inc. | PFE | 7 | PHASE3 | RSVpreF, ABRYSVO, ABRYSVO Vaccination, RSVpreF vaccine |
| Enanta Pharmaceuticals, Inc. | ENTA | 1 | PHASE2 | zelicapavir |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Low-dose RSV mRNA vaccine |
| Sanofi SA Sponsored ADR | SNY | 2 | — | Nirsevimab |
| AstraZeneca PLC | AZN | 1 | NA | Palivizumab /kg |